An announcement from Legend Biotech ( (LEGN) ) is now available.
On March 11, 2025, Legend Biotech reported its financial results for the fourth quarter and full year 2024, highlighting significant achievements such as CARVYKTI® net sales reaching approximately $963 million for the year. The company treated over 5,000 patients and initiated commercial production at a Novartis facility. Spain’s national health system approved reimbursement for CARVYKTI® in specific multiple myeloma settings, enhancing its market reach. Legend Biotech’s financial position remains strong with $1.1 billion in cash and equivalents, providing a runway into 2026. The company also reported a net income of $26.3 million for the fourth quarter, a significant improvement from the previous year’s loss, driven by increased revenue and foreign exchange gains.
More about Legend Biotech
Legend Biotech Corporation is a global leader in cell therapy, primarily focusing on the development and commercialization of innovative treatments for cancer, including CARVYKTI®, a CAR-T cell therapy for multiple myeloma. The company is committed to advancing its position in the cell therapy industry through strategic partnerships and investments in research and development.
YTD Price Performance: -2.02%
Average Trading Volume: 1,278,443
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.24B
See more data about LEGN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com